Analysts expect FibroGen Inc (NASDAQ:FGEN) to post sales of $50.68 million for the current fiscal quarter, according to Zacks Investment Research. Five analysts have provided estimates for FibroGen’s earnings, with estimates ranging from $10.40 million to $81.90 million. FibroGen reported sales of $108.05 million in the same quarter last year, which indicates a negative year-over-year growth rate of 53.1%. The company is scheduled to report its next quarterly earnings report on Wednesday, February 26th.
According to Zacks, analysts expect that FibroGen will report full-year sales of $299.30 million for the current year, with estimates ranging from $259.00 million to $330.50 million. For the next year, analysts expect that the business will post sales of $307.61 million, with estimates ranging from $221.70 million to $544.40 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research analysts that cover FibroGen.
FibroGen (NASDAQ:FGEN) last posted its earnings results on Monday, November 11th. The biopharmaceutical company reported ($0.57) EPS for the quarter, beating the consensus estimate of ($0.59) by $0.02. The firm had revenue of $33.17 million for the quarter, compared to analyst estimates of $31.61 million. FibroGen had a return on equity of 7.33% and a net margin of 11.81%. FibroGen’s revenue for the quarter was up 14.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.50) earnings per share.
In other FibroGen news, SVP Christine Chung sold 5,625 shares of the company’s stock in a transaction on Thursday, November 14th. The shares were sold at an average price of $34.74, for a total value of $195,412.50. Following the completion of the transaction, the senior vice president now owns 145,253 shares in the company, valued at $5,046,089.22. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Kalevi Kurkijarvi sold 6,000 shares of the company’s stock in a transaction on Monday, December 9th. The shares were sold at an average price of $47.50, for a total transaction of $285,000.00. Following the completion of the transaction, the director now owns 34,400 shares of the company’s stock, valued at approximately $1,634,000. The disclosure for this sale can be found here. Insiders sold 41,495 shares of company stock worth $1,636,069 in the last three months. 8.96% of the stock is currently owned by corporate insiders.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Captrust Financial Advisors acquired a new position in FibroGen in the second quarter valued at $90,000. US Bancorp DE boosted its stake in FibroGen by 79.7% in the second quarter. US Bancorp DE now owns 2,172 shares of the biopharmaceutical company’s stock valued at $98,000 after acquiring an additional 963 shares in the last quarter. Usca Ria LLC acquired a new position in FibroGen in the third quarter valued at $123,000. Convergence Investment Partners LLC acquired a new position in FibroGen in the third quarter valued at $137,000. Finally, Nisa Investment Advisors LLC boosted its stake in FibroGen by 729.8% in the third quarter. Nisa Investment Advisors LLC now owns 3,900 shares of the biopharmaceutical company’s stock valued at $144,000 after acquiring an additional 3,430 shares in the last quarter. Institutional investors own 68.71% of the company’s stock.
NASDAQ:FGEN traded down $0.95 during trading hours on Monday, hitting $46.69. The company’s stock had a trading volume of 494,059 shares, compared to its average volume of 657,633. The stock has a market capitalization of $4.13 billion, a P/E ratio of -45.33 and a beta of 1.84. The stock has a fifty day moving average of $40.91 and a 200-day moving average of $41.84. The company has a current ratio of 9.01, a quick ratio of 8.95 and a debt-to-equity ratio of 0.07. FibroGen has a 52-week low of $32.33 and a 52-week high of $61.23.
FibroGen Company Profile
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.
Read More: Example of operating income, EBIT and EBITDA
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.